The Research, Scholarship, and Artistic Achievement Awards nomination deadline has been extended to May 31, 2024. Click here for more information.

Engineered mesenchymal stem cells for the prevention and treatment of HIV

Background

Tulane University is actively seeking commercial entities to further develop and commercialize compositions to treat and prevent HIV using engineered knockout mesenchymal stem cells.

Applications

MSCs may be used to prevent HIV infection-exposure or post-exposure. MSC compositions may be used to treat HIV infection alone or in combination with anti-retroviral therapy. Knockout MSCs were able to differentiate into HIV-resistant hematopoietic stem cells.

Inventors

Intellectual Property

Available For

Exclusive License in a Field
Non-exclusive License
Scientific Collaboration

For more information, please contact: